Journal article
Skeletal myoblast transplantation: no MAGIC bullet for ischemic cardiomyopathy
Nature clinical practice cardiovascular medicine, v 5(9), pp 520-521
01 Sep 2008
PMID: 18648335
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Therapies for end-stage heart failure are limited by the donor shortage for heart transplantation and the shortcomings of left ventricular assist devices for destination therapy. Treatments that use stem cells to 'rebuild' the myocardium are, therefore, desirable. Such therapies use either stem cells derived from bone marrow or skeletal myoblasts. In clinical trials, however, neither method of administration has demonstrated an improvement in ventricular function. The MAGIC trial was a randomized, placebo-controlled study of high and low doses of skeletal myoblasts injected into the myocardium of patients with MI undergoing CABG surgery. No difference in left ventricular ejection fraction was noted in the cell-treated groups when compared with controls, although patients who received the high dose of myoblasts had a decrease in ventricular dimensions, raising the possibility of an antiremodeling effect. A higher incidence of ventricular arrhythmias was observed in the myoblast groups than in control patients.
Metrics
Details
- Title
- Skeletal myoblast transplantation: no MAGIC bullet for ischemic cardiomyopathy
- Creators
- Howard J. Eisen - Drexel University
- Publication Details
- Nature clinical practice cardiovascular medicine, v 5(9), pp 520-521
- Publisher
- Springer Nature
- Number of pages
- 2
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000258581000005
- Scopus ID
- 2-s2.0-50649104813
- Other Identifier
- 991019330793104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Cardiac & Cardiovascular Systems